Quarterly ResultMay 6, 2026, 04:08 PM
Niagen Bioscience Q1 Net Sales $31.5M; Net Income $6.3M; EPS $0.07
AI Summary
Niagen Bioscience reported first-quarter 2026 financial results with net sales increasing 3% to $31.5 million and net income rising to $6.3 million, including a $4.8 million gain from a divestiture. The company also announced several strategic operational advancements, including the launch of a telehealth platform for Niagen Plus, expansion into the skincare category, and the establishment of a USP monograph for NRCL. Despite a decrease in Adjusted EBITDA to $3.8 million and negative operating cash flow, the company updated its full-year 2026 outlook, reaffirming net sales growth of 10-15% (excluding the divested segment) and improving its G&A expense outlook.
Key Highlights
- Net sales increased 3% to $31.5 million in Q1 2026.
- Net income rose to $6.3 million, including a $4.8 million gain from divestiture.
- Diluted earnings per share (EPS) were $0.07 for the quarter.
- Gross margin improved to 63.5%.
- Adjusted EBITDA was $3.8 million.
- Used $1.2 million in operating cash flow, ending with $66.5 million cash.
- Repurchased $2.4 million of common stock; board approved $20 million program.
- Updated 2026 outlook: Net sales growth 10-15%; G&A expense up $3-4 million.